CJC-1295 Reference

Plain English

What it is

CJC-1295 is a lab-made peptide studied as a way to prompt the body to release more of its own growth hormone in natural bursts. It is not an FDA-approved medicine. It is sold and used as a research chemical, and it comes in two different forms (a short-acting one and a longer-acting one) that are actually different molecules and are not interchangeable.

What people use it for

In the peptide community it is often talked about alongside another peptide called ipamorelin to try to boost the body's growth-hormone bursts. People discuss it for better sleep, body composition, and recovery, but the reported effects tend to be small and to build up slowly.

What the science shows

Most published human research is on the longer-acting form, which raised growth hormone and a related blood marker called IGF-1 while keeping the natural rhythm of those bursts in a small study of healthy men. There are no large, long-term trials showing it improves real health outcomes or is safe over time, so most of what people report stays anecdotal.

The catch

There is no FDA-approved CJC-1295 product, and the FDA has flagged significant safety concerns about peptides like this in compounding, including the risk that the body's immune system reacts to it (immunogenicity). The FDA also said there is not enough data to rule out the same kinds of risks seen with approved growth-hormone stimulators. Because it is unapproved, quality and labeling can vary, the two forms are easy to mix up, and amounts can be measured wrong.

Reference summary

Published human data are primarily on the long-acting DAC-linked form, which increased GH and IGF-1 while preserving pulsatility in healthy men. No-DAC and DAC products are pharmacologically distinct, and long-term outcome data remain limited.

Regulatory and posture

Categories

GH Release, Longevity

Aliases

CJC-1295 acetate, CJC-1295 no DAC, CJC-1295 with DAC, GHRH analog, Mod GRF 1-29

Evidence posture

human - Human data are mainly small DAC-form endocrine studies, not broad long-term outcome trials.

Regulatory status

No FDA-approved CJC-1295 drug label. FDA lists CJC-1295 among bulk substances with safety-risk concerns for compounding.

Content review status

research reference

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• Injection-site rotation overview - Public overview of the Pro site-rotation planner.